Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189279 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT01189279 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 42 participants.
The verdict
NCT01189279, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. Part 2 will begin after Part 1 has completed.
Interventions
- DRUG bimatoprost Formulation A
- DRUG bimatoprost Formulation B
- DRUG bimatoprost Formulation C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01189279
The ClinicalTrials.gov registry entry for NCT01189279 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bimatoprost Formulation A is the first listed.
NCT01189279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01189279 about?
NCT01189279 is a clinical study titled "Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia". This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost will be investigated in Part 1 and a third formulation of bimatoprost will be investigated in Part 2. ...
What is the current status of trial NCT01189279?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2010-10. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01189279?
The interventions under investigation include: bimatoprost Formulation A (DRUG), bimatoprost Formulation B (DRUG), bimatoprost Formulation C (DRUG).
Who is sponsoring clinical trial NCT01189279?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.